ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3L

Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial

Jon T. Giles1, Naveed Sattar2, Sherine E. Gabriel3, Paul M. Ridker4, Steffen Gay5, Charles Warne6, David Musselman7, Laura Brockwell6, Emma Shittu6, Micki Klearman7 and Thomas Fleming8, 1Columbia University, College of Physicians and Surgeons, New York, NY, 2Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, 3Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 4Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, MA, 5University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland, 6Roche Products Ltd., Welwyn Garden City, United Kingdom, 7Genentech, South San Francisco, CA, 8University of Washington, Department of Biostatistics, Seattle, WA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: October 19, 2016

Keywords: etanercept, Late-Breaking 2016, outcomes and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: ACR Late-breaking Abstract Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Treatment of rheumatoid arthritis (RA) with tocilizumab (TCZ), a humanized monoclonal antibody directed against the IL-6 receptor, is associated with clinical efficacy and marked reduction in systemic inflammatory markers associated with atherogenesis and atherothrombosis, but treatment-associated increases in low-density lipoprotein (LDL-C) have called into question the net cardiovascular risk-benefit ratio of TCZ in RA.

Methods: Seropositive RA patients with active disease (≥8 swollen and ≥8 tender joints and CRP >3 mg/L) and inadequate response to ≥1 nonbiologic DMARD were randomized 1:1 to receive open-label TCZ 8 mg/kg infused monthly or etanercept (ETA) 50 mg injected weekly. Enrollment was restricted to patients ≥50 years of age with ≥1 cardiovascular disease (CVD) risk factor, extra-articular RA manifestations, or history of a CVD event. The primary outcome was the comparison of incident major adverse CVD event (MACE), defined as CVD death, nonfatal myocardial infarction or nonfatal stroke, for TCZ vs ETA. Rates of other CVD events and non-CVD safety outcomes were explored as secondary outcomes. Lipid levels were tracked throughout the trial. CVD events were adjudicated by an independent committee. The study was powered to rule out ≥80% relative hazard of MACE for TCZ vs ETA.

Results: A total of 3080 RA patients were enrolled (TCZ n=1538; ETA n=1542), and 2957 (96%) completed the study with a full assessment of CVD events. Average follow-up time was 3.2 years. Early discontinuation of randomized treatment occurred in 23% of ETA- vs 26% of TCZ-treated patients. Baseline characteristics (mean age 61 years, 22% male, 29% current smokers, 71% with hypertension, 18% with diabetes, mean CRP 19.3 mg/L) were balanced between treatment groups. A total of 161 MACE qualified for inclusion into the primary analysis. In the intention-to-treat analysis, 83 MACE occurred over 4900 PYs in the TCZ arm vs 78 over 4891 PYs in the ETA arm (HR 1.05; 95% CI 0.77, 1.43). HRs for TCZ vs ETA for other secondary CVD outcomes are summarized in the Table. By week 4, total cholesterol, LDL-C, HDL-C, and triglycerides increased significantly in the TCZ arm compared with the ETA arm, with median LDL-C increasing 12% for TCZ vs 1% for ETA. Thereafter, average levels remained consistent to trial conclusion. The overall rate of adverse events, serious infections, and medically confirmed gastrointestinal perforations was numerically higher for TCZ vs ETA.

Conclusion: This comparative study of TCZ with ETA excluded a >43% relative increase in the hazard of MACE (HR 1.05; 95% CI 0.77, 1.43), with an estimated 5% increase in TCZ compared with ETA among RA patients with severe active disease and elevated baseline CVD risk. Average treatment-associated increases in LDL-C were higher for TCZ vs ETA. The CVD safety of TCZ relative to ETA should be interpreted in the context of its non-CVD safety and clinical efficacy.

Table. Hazard Ratios of Major End Points for Tocilizumab vs Etanercept

 

Etanercept

N = 1542

Tocilizumab

N = 1538

Tocilizumab

vs Etanercept

 First Events, n

First Events, n

HRa

95% CI

MACE-ITT population

78

83

1.05

0.77, 1.43

MACE-OT population

52

57

1.11

0.76, 1.62

CVD death

35

36

1.03

0.64, 1.63

Nonfatal MI

31

28

0.89

0.54, 1.49

Nonfatal stroke

15

24

1.53

0.80, 2.92

All-cause mortality

64

64

0.99

0.70, 1.41

Expanded composite end pointb

84

84

0.99

0.73, 1.34

Hospitalized for HF

8

12

1.50

0.61, 3.67

MACE + hospitalized for HF

85

90

1.05

0.78, 1.41

Fatal + nonfatal MI

32

29

0.90

0.54, 1.48

Fatal + nonfatal stroke

16

26

1.55

0.83, 2.90

CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; ITT, intention-to-treat; MACE, major adverse cardiovascular event (ie, any CVD death, nonfatal MI, and nonfatal stroke); MI, myocardial infarction; OT, on-treatment; PY, patient-years. aBased on time to first event; Cox regression model stratified by previous exposure to anti−TNF and CV history. bExpanded composite end point defined as MACE + nonelective coronary revascularization and hospitalization for unstable angina.

 

 

   


Disclosure: J. T. Giles, Genentech and Biogen IDEC Inc., 5; N. Sattar, Roche, 9; S. E. Gabriel, Genentech, 5,Sanofi, 5,UCB, 5; P. M. Ridker, Genentech and Biogen IDEC Inc., 5; S. Gay, Roche/Genentech, 5,Pfizer, 2,Pfizer, 5,GlaxoSmithKline, 2,Novartis Pharmaceutical Corporation, 5,Tonix, 5,Lilly, 5; C. Warne, Roche Products Ltd., 3; D. Musselman, Roche/Genentech, 3; L. Brockwell, Roche/Genentech, 3; E. Shittu, Roche Products Ltd., 3; M. Klearman, Roche/Genentech, 1,Roche/Genentech, 3; T. Fleming, Roche/Genentech, 5.

To cite this abstract in AMA style:

Giles JT, Sattar N, Gabriel SE, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming T. Comparative Cardiovascular Safety of Tocilizumab Vs Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-cardiovascular-safety-of-tocilizumab-vs-etanercept-in-rheumatoid-arthritis-results-of-a-randomized-parallel-group-multicenter-noninferiority-phase-4-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.